Microba Life Sciences (F3Y) Stock Overview

Provides microbiome testing, supplements, and analysis services in Australia, Europe, New Zealand, the United Arab Emirates, the United Kingdom, the United States, Asia, and Ireland. More details

F3Y fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	2/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Rewards

Revenue is forecast to grow 27.72% per year

Risk Analysis

Shareholders have been substantially diluted in the past year

Currently unprofitable and not forecast to become profitable over the next 3 years

Does not have a meaningful market cap (€55M)

Volatile share price over the past 3 months compared to the German market

F3Y Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

View Stock Community

Microba Life Sciences Limited Competitors

Price History & Performance

Summary of share price highs, lows and changes for Microba Life Sciences
Historical stock prices
Current Share Price	AU$0.045
52 Week High	AU$0.054
52 Week Low	AU$0.042
Beta	2.39
1 Month Change	-3.40%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	7.06%

Recent updates

Shareholder Returns

	F3Y	DE Healthcare	DE Market
7D	-4.2%	-0.8%	3.8%
1Y	n/a	30.5%	16.7%

Return vs Industry: Insufficient data to determine how F3Y performed against the German Healthcare industry.

Return vs Market: Insufficient data to determine how F3Y performed against the German Market.

Price Volatility

Is F3Y's price volatile compared to industry and market?
F3Y volatility
F3Y Average Weekly Movement	9.2%
Healthcare Industry Average Movement	5.2%
Market Average Movement	5.1%
10% most volatile stocks in DE Market	11.4%
10% least volatile stocks in DE Market	2.5%

Stable Share Price: F3Y's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: Insufficient data to determine F3Y's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2017	n/a	Luke Reid	microba.com

Microba Life Sciences Limited provides microbiome testing, supplements, and analysis services in Australia, Europe, New Zealand, the United Arab Emirates, the United Kingdom, the United States, Asia, and Ireland. It operates in two segments, Testing Services and Supplements, and Research and Development. The company also develops pathology, therapeutics, and diagnostics services based on the human gut microbiome.

Microba Life Sciences Limited Fundamentals Summary

How do Microba Life Sciences's earnings and revenue compare to its market cap?
F3Y fundamental statistics
Market cap	€30.65m
Earnings (TTM)	-€8.36m
Revenue (TTM)	€8.76m

3.5x

P/S Ratio

-3.7x

P/E Ratio

Is F3Y overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
F3Y income statement (TTM)
Revenue	AU$15.67m
Cost of Revenue	AU$8.23m
Gross Profit	AU$7.44m
Other Expenses	AU$22.38m
Earnings	-AU$14.94m

Last Reported Earnings

Jun 30, 2025

Next Earnings Date

n/a

Earnings per share (EPS)	-0.025
Gross Margin	47.49%
Net Profit Margin	-95.34%
Debt/Equity Ratio	3.7%

How did F3Y perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/09/05 20:37
End of Day Share Price	2025/09/05 00:00
Earnings	2025/06/30
Annual Earnings	2025/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Microba Life Sciences Limited is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Tara Speranza	Bell Potter
Thomas Wakim	Bell Potter
Elyse Shapiro	Canaccord Genuity

Microba Life Sciences LimitedDB:F3Y Stock Report